Improved organ transplant preservation solution with modified albumin
This technology is an organ preservation solution that extends organ viability by preventing glycation.
Unmet Need: Glycation prevention solution for preservation of organ transplants
The shelf-life of organ transplants is limited by tissue swelling and degeneration during storage. Glycation, in which excess sugars bind to proteins or lipids, is one of the main drivers of tissue degeneration. Advanced glycation end products build up and damage tissue structure and mechanical integrity, leading to complications in the transplanted organ’s performance. Although various strategies exist to prolong organ storage, none can effectively prevent glycation during storage.
The Technology: Modified albumin solution for the prevention of glycation in organ transplants
This technology is a solution for organ preservation that uses modified amino acids found in albumin via site-directed mutagenesis to prevent glycation. Organ preservation solution typically contains albumin, which is known to undergo glycation. Modification of albumin amino acids to inhibit binding with sugars can prevent the formation of harmful advanced glycation end products, better preserving the organ’s physiologic structure and function for transplantation.
Applications:
- Preservation solution for organ transplants
- Preservation solution for artificial organs
- Preservation solution for explant tissues for research
- Anti-aging formulations for skincare
Advantages:
- Compatible with current transplant preservation systems
- Extends organ storage life
- Preserves organ structure and function
Lead Inventor:
Related Publications:
Tech Ventures Reference:
- Licensing Contact: Jerry Kokoshka